Cargando…
Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications
Basic fibroblast growth factor (FGF)-2 has been shown to regulate many cellular functions including cell proliferation, migration, and differentiation, as well as angiogenesis in a variety of tissues, including skin, blood vessel, muscle, adipose, tendon/ligament, cartilage, bone, tooth, and nerve....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356611/ https://www.ncbi.nlm.nih.gov/pubmed/32498439 http://dx.doi.org/10.3390/pharmaceutics12060508 |
_version_ | 1783558529348534272 |
---|---|
author | Benington, Leah Rajan, Gunesh Locher, Cornelia Lim, Lee Yong |
author_facet | Benington, Leah Rajan, Gunesh Locher, Cornelia Lim, Lee Yong |
author_sort | Benington, Leah |
collection | PubMed |
description | Basic fibroblast growth factor (FGF)-2 has been shown to regulate many cellular functions including cell proliferation, migration, and differentiation, as well as angiogenesis in a variety of tissues, including skin, blood vessel, muscle, adipose, tendon/ligament, cartilage, bone, tooth, and nerve. These multiple functions make FGF-2 an attractive component for wound healing and tissue engineering constructs; however, the stability of FGF-2 is widely accepted to be a major concern for the development of useful medicinal products. Many approaches have been reported in the literature for preserving the biological activity of FGF-2 in aqueous solutions. Most of these efforts were directed at sustaining FGF-2 activity for cell culture research, with a smaller number of studies seeking to develop sustained release formulations of FGF-2 for tissue engineering applications. The stabilisation approaches may be classified into the broad classes of ionic interaction modification with excipients, chemical modification, and physical adsorption and encapsulation with carrier materials. This review discusses the underlying causes of FGF-2 instability and provides an overview of the approaches reported in the literature for stabilising FGF-2 that may be relevant for clinical applications. Although efforts have been made to stabilise FGF-2 for both in vitro and in vivo applications with varying degrees of success, the lack of comprehensive published stability data for the final FGF-2 products represents a substantial gap in the current knowledge, which has to be addressed before viable products for wider tissue engineering applications can be developed to meet regulatory authorisation. |
format | Online Article Text |
id | pubmed-7356611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73566112020-07-22 Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications Benington, Leah Rajan, Gunesh Locher, Cornelia Lim, Lee Yong Pharmaceutics Review Basic fibroblast growth factor (FGF)-2 has been shown to regulate many cellular functions including cell proliferation, migration, and differentiation, as well as angiogenesis in a variety of tissues, including skin, blood vessel, muscle, adipose, tendon/ligament, cartilage, bone, tooth, and nerve. These multiple functions make FGF-2 an attractive component for wound healing and tissue engineering constructs; however, the stability of FGF-2 is widely accepted to be a major concern for the development of useful medicinal products. Many approaches have been reported in the literature for preserving the biological activity of FGF-2 in aqueous solutions. Most of these efforts were directed at sustaining FGF-2 activity for cell culture research, with a smaller number of studies seeking to develop sustained release formulations of FGF-2 for tissue engineering applications. The stabilisation approaches may be classified into the broad classes of ionic interaction modification with excipients, chemical modification, and physical adsorption and encapsulation with carrier materials. This review discusses the underlying causes of FGF-2 instability and provides an overview of the approaches reported in the literature for stabilising FGF-2 that may be relevant for clinical applications. Although efforts have been made to stabilise FGF-2 for both in vitro and in vivo applications with varying degrees of success, the lack of comprehensive published stability data for the final FGF-2 products represents a substantial gap in the current knowledge, which has to be addressed before viable products for wider tissue engineering applications can be developed to meet regulatory authorisation. MDPI 2020-06-02 /pmc/articles/PMC7356611/ /pubmed/32498439 http://dx.doi.org/10.3390/pharmaceutics12060508 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Benington, Leah Rajan, Gunesh Locher, Cornelia Lim, Lee Yong Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title | Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title_full | Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title_fullStr | Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title_full_unstemmed | Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title_short | Fibroblast Growth Factor 2—A Review of Stabilisation Approaches for Clinical Applications |
title_sort | fibroblast growth factor 2—a review of stabilisation approaches for clinical applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356611/ https://www.ncbi.nlm.nih.gov/pubmed/32498439 http://dx.doi.org/10.3390/pharmaceutics12060508 |
work_keys_str_mv | AT beningtonleah fibroblastgrowthfactor2areviewofstabilisationapproachesforclinicalapplications AT rajangunesh fibroblastgrowthfactor2areviewofstabilisationapproachesforclinicalapplications AT lochercornelia fibroblastgrowthfactor2areviewofstabilisationapproachesforclinicalapplications AT limleeyong fibroblastgrowthfactor2areviewofstabilisationapproachesforclinicalapplications |